Global Tourette Syndrome (TS) – Epidemiology Insights and Forecast Report (Top 32 Markets) – 2020 To 2040
Global Tourette Syndrome (TS)
Epidemiology Insights
Thelansis’s “Global Tourette Syndrome (TS) Epidemiology Insights
and Forecast Report (Top 32 Markets) –
2020 To 2040″ provides an analysis of disease burden, characterized by disease
definition, kidney biopsy cases, prevalence, incidence, diagnosed cases,
severity, comorbidities, and clinical manifestations. Potential patient flow
dynamics in disease burden are driven by shifts in demographic indicators and
their correlation with age and gender distribution over time. Changes in the
reported cases and long-term survival of patients may depend on diet,
lifestyle, comorbid conditions, and the availability of interventions or therapies
for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa,
South / Latin America).
Global Tourette Syndrome (TS) Overview
Tourette syndrome (TS) is a complex
neurodevelopmental disorder clinically defined by the presence of multiple
motor tics and at least one vocal (phonic) tic that persist and fluctuate in
severity for more than a year, with an onset prior to age 18. The underlying
pathophysiology is strongly linked to dopamine dysregulation within the
cortico-striato-thalamo-cortical (CSTC) circuitry. TS falls under the broader
spectrum of tic disorders, which modern diagnostic frameworks classify
alongside Provisional Tic Disorder (lasting less than a year) and Persistent
Motor or Vocal Tic Disorder. Clinically, TS follows a classic waxing and waning
course, typically peaking during early adolescence, and is highly associated
with neurobehavioral comorbidities, most notably ADHD and OCD. Because there
are currently no disease-modifying therapies to cure the root neurological
dysfunction, management is strictly symptom-directed; the modern standard of
care prioritizes Comprehensive Behavioral Intervention for Tics (CBIT), strategically
escalating to targeted pharmacotherapy—such as alpha-2 adrenergic agonists,
dopamine antagonists, or VMAT2 inhibitors—only when tics cause profound
physical discomfort or significantly disrupt psychosocial functioning.
Market
Definition:
- North America (United States, Canada)
- Europe (Austria, Belgium, Czech
Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands,
Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United
Kingdom)
- Middle East (Saudi Arabia, UAE,
Kuwait, Turkey)
- Asia Pacific (Australia, China, Hong
Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines,
Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt, Nigeria, South Africa,
Morocco)
- South / Latin America (Argentina,
Brazil, Chile, Colombia, Mexico, Peru)
Deliverables
format and updates*:
- Access to an interactive epidemiology
platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional
findings
- Country-specific
findings
- Others*: regular updates,
customizations, epidemiologist support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the content. Countries, subpopulations, and years of forecast can be
customized as per client requirements.
Key business
questions answered:
- 20-year historical and forecast data
(2020–2040)
- Disease definition based on globally
accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage
by year and geography
- Detailed segmentation by age, gender,
subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g.,
staging/classification/severity)
Insights
driven by robust research and estimates:
- Published literature (e.g.,
peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR
datasets
- Proprietary mathematical models
(e.g., incidence-survival model;
incidence- recurrence/progression-survival model
Comments
Post a Comment